B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| 2 | Miscellaneous | 12.42% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
BioAge Labs
BIOA
$249M
| $21M | 0.7% |
+1,200,587
| New | +$23.1M |
2026 Q1
0 quarters
|
|
52
CVS Health
CVS
$116B
| $20.9M | 0.7% |
290,700
-273,500
| -48% | -$21.1M |
2025 Q3
2 quarters
|
|
53
Tarsus Pharmaceuticals
TARS
$3.38B
| $18.6M | 0.62% |
+265,715
| New | +$18.6M |
2026 Q1
0 quarters
|
|
54
Elevance Health
ELV
$92.8B
| $18.2M | 0.61% |
+62,080
| New | +$20.4M |
2026 Q1
0 quarters
|
|
55
OrthoPediatrics
KIDS
$581M
| $17.5M | 0.58% |
1,100,370
| – | – |
2022 Q4
13 quarters
|
|
56
enGene Therapeutics
ENGN
$105M
| $16.7M | 0.56% |
2,456,870
-674,449
| -22% | -$6M |
2025 Q3
2 quarters
|
|
57
Nektar Therapeutics
NKTR
$1.26B
| $16M | 0.53% |
+222,701
| New | +$12.7M |
2026 Q1
0 quarters
|
|
58
Acadia Healthcare
ACHC
$2.95B
| $15.1M | 0.5% |
+645,900
| New | +$11.7M |
2026 Q1
0 quarters
|
|
59
Oric Pharmaceuticals
ORIC
$1.2B
| $14.3M | 0.48% |
+1,128,040
| New | +$12.8M |
2026 Q1
0 quarters
|
|
60
Aveanna Healthcare
AVAH
$2.7B
| $14.2M | 0.47% |
+2,203,506
| New | +$17M |
2026 Q1
0 quarters
|
|
61
X4 Pharmaceuticals
XFOR
$243M
| $13.5M | 0.45% |
3,272,954
-95,950
| -3% | -$359K |
2025 Q4
1 quarter
|
|
62
Kiniksa Pharmaceuticals
KNSA
$6.15B
| $13.1M | 0.44% |
272,522
-41,301
| -13% | -$1.83M |
2024 Q1
8 quarters
|
|
63
Evolus
EOLS
$477M
| $12.8M | 0.43% |
3,105,209
| – | – |
2025 Q4
1 quarter
|
|
64
TG Therapeutics
TGTX
$8.32B
| $11.9M | 0.4% |
+358,800
| New | +$10.7M |
2026 Q1
0 quarters
|
|
65
Surrozen
SRZN
$279M
| $11.5M | 0.38% |
396,100
-73,900
| -16% | -$1.77M |
2025 Q2
3 quarters
|
|
66
Centene
CNC
$34.7B
| $10.8M | 0.36% |
+330,000
| New | +$13.5M |
2026 Q1
0 quarters
|
|
67
Climb Bio
CLYM
$591M
| $10.5M | 0.35% |
+1,529,675
| New | +$8.82M |
2026 Q1
0 quarters
|
|
68
Compass Therapeutics
CMPX
$158M
| $10.4M | 0.35% |
1,965,106
-821,672
| -29% | -$4.74M |
2025 Q4
1 quarter
|
|
69
Ionis Pharmaceuticals
IONS
$7.1B
| $9.83M | 0.33% |
+130,862
| New | +$10.3M |
2026 Q1
0 quarters
|
|
70
Helix Acquisition Corp III
HLXC
$229M
| $9.27M | 0.31% |
+900,000
| New | +$9.21M |
2026 Q1
0 quarters
|
|
71
Vor Biopharma
VOR
$1.11B
| $8.33M | 0.28% |
+466,774
| New | +$6.58M |
2026 Q1
0 quarters
|
|
72
Revolution Medicines
RVMD
$41.5B
| $8.26M | 0.28% |
+84,900
| New | +$8.57M |
2026 Q1
0 quarters
|
|
73
GRAIL Inc
GRAL
$6.24B
| $7.38M | 0.25% |
142,755
| – | – |
2025 Q4
1 quarter
|
|
74
Aclaris Therapeutics
ACRS
$498M
| $6.37M | 0.21% |
+1,699,116
| New | +$5.73M |
2026 Q1
0 quarters
|
|
75
Denali Therapeutics
DNLI
$2.86B
| $5.69M | 0.19% |
+296,324
| New | +$5.9M |
2026 Q1
0 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2026 Portfolio in Review
As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.
- Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
- Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
- Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
- Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
- Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
- Braidwell opened 28 new positions and closed 14 in Q1 2026.
- Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.
Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.